Journal article
New oral anticoagulants in atrial fibrillation
Abstract
Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet inhibitor) and vitamin K antagonists (VKAs; oral anticoagulants), including warfarin, are the only approved antithrombotic therapies for stroke prevention in patients with AF. Although effective, VKAs have unpredictable pharmacological effects, requiring regular coagulation monitoring and dose adjustment to maintain effects within the …
Authors
Turpie AGG
Journal
European Heart Journal, Vol. 29, No. 2, pp. 155–165
Publisher
Oxford University Press (OUP)
Publication Date
January 2008
DOI
10.1093/eurheartj/ehm575
ISSN
0195-668X